On May 30, 2023 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that a late-breaking abstract with updated data from the Phase 1 trial of the Company’s menin inhibitor, ziftomenib, has been accepted for oral presentation at the 2023 European Hematology Association (EHA) (Free EHA Whitepaper) Congress in Frankfurt, Germany (Press release, Kura Oncology, MAY 30, 2023, View Source [SID1234632216]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Late-breaking abstract # LB2713, entitled "Activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed/refractory NPM1-mutated AML," will be presented at the late-breaking oral session from 9:45-11:15 CET on Sunday, June 11, 2023. Late-breaking abstracts are scheduled for publication on the EHA (Free EHA Whitepaper) website at 16:00 CET on Thursday, June 1, 2023.

Management will host a virtual investor event featuring company management and investigators from the Phase 1 trial of ziftomenib at 8:00 a.m. ET on Monday, June 12, 2023. The event will be webcast live and can be accessed on the Investors section of Kura’s website at www.kuraoncology.com. An archived replay will be available shortly after the conclusion of the live event.